Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash & Equivalents: 2016-2025

Historic Cash & Equivalents for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $90.0 million.

  • UroGen Pharma's Cash & Equivalents fell 27.92% to $90.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.0 million, marking a year-over-year decrease of 27.92%. This contributed to the annual value of $172.0 million for FY2024, which is 81.04% up from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Cash & Equivalents is $90.0 million, which was down 3.08% from $92.9 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Cash & Equivalents ranged from a high of $220.0 million in Q2 2024 and a low of $20.1 million during Q2 2023.
  • In the last 3 years, UroGen Pharma's Cash & Equivalents had a median value of $104.0 million in 2025 and averaged $109.7 million.
  • As far as peak fluctuations go, UroGen Pharma's Cash & Equivalents slumped by 65.33% in 2023, and later surged by 992.92% in 2024.
  • UroGen Pharma's Cash & Equivalents (Quarterly) stood at $44.4 million in 2021, then rose by 24.91% to $55.4 million in 2022, then skyrocketed by 71.46% to $95.0 million in 2023, then spiked by 81.04% to $172.0 million in 2024, then fell by 27.92% to $90.0 million in 2025.
  • Its Cash & Equivalents was $90.0 million in Q3 2025, compared to $92.9 million in Q2 2025 and $104.0 million in Q1 2025.